A Phase I, Single-centre, Multiple-dose, Placebo-controlled Crossover Study to Investigate the Pharmacodynamic Effects of CT327 (0.1% Topical Cream) on Intra-dermal Nerve Growth Factor (NGF) and Evoked Pain Responses, in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2014
At a glance
- Drugs Pegcantratinib (Primary)
- Indications Neuropathic pain
- Focus Pharmacodynamics
- Sponsors Creabilis SA
- 07 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Feb 2011 Actual initiation date (Jan 2011) added as reported by ClinicalTrials.gov.